PLCG2 and B-cell chronic lymphocytic leukemia: DAPK3 is activated downstream of BTK and PLCγ2, suggesting that it could be an attractive alternative to ibrutinib, particularly in CLL cells for which relapse is correlated with mutations of both upstream proteins.